UCB0599

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

221 competitors in Epilepsy

#DrugCompanyPhaseTrials

1

Briviact

UCB

Phase 3

142

Epidiolex

Jazz Pharmaceuticals

Phase 3

93

Dayvigo

Eisai

Phase 3

14

Depacon

AbbVie

Phase 3

15

Zonegran

AAzurity Pharmaceuticals

Phase 3

56

Actemra

Roche

Phase 3

—7

Fintepla

IImmedica Pharma AB

Phase 3

48

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

39

Narcan

SScienture

Phase 3

110

GWP42003-P

Jazz Pharmaceuticals

Phase 3

1Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ART1 trial

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

Completed·UCB·Phase 1·NCT05845645·73 enrolled

Parkinson's Disease (PD)1 trial

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

Completed·UCB·Phase 1·NCT04875962·31 enrolled

Parkinson's Disease1 trial

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Completed·UCB·Phase 2·NCT04658186·496 enrolled

Details

Drug Info

Related News